Login
Search
Search
0 Dates
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
Characterization of plasma acylcarnitines in obese patients with severe aortic stenosis
Session:
Posters - O. Basic Science
Speaker:
Glória Conceição
Congress:
CPC 2021
Topic:
O. Basic Science
Theme:
36. Basic Science
Subtheme:
36.3 Basic Science - Cardiac Diseases
Session Type:
Posters
FP Number:
---
Authors:
Glória Conceição; Jennifer Mancio; Joana Santos-Gomes; Adelino f. Leite-Moreira; Nuno Bettencourt; Hugo Rocha; Inês Falcão-Pires
Abstract
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif">Energy metabolism is central to cardiac health and disease. High adenosine triphosphate (ATP) turnover is required to maintain contractile function. Recently, dysregulation of fatty acid oxidation, reflected in acylcarnitines’ plasma levels, has been recognized as an important player of obesity pathophysiology. The aim of the present study was to characterize the acylcarnitines profile in coronary sinus blood aortic stenosis (AS) patients throughout a spectrum of obesity. </span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif">In a cohort of patients with severe AS, plasma acylcarnitines were determined in 14 obese and 18 non-obese fasting patients by the standard method of butylation and analysis by tandem mass spectrometry (MS/MS). Afterwards, we examined their association with adiposity parameters and cardiac function parameters. </span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif">Obese patients showed a different spectrum of short-, medium- and long-chain acylcarnitines preference compared to non-obese. The levels of total medium-chain acylcarnitines were markedly elevated, representing its decreased utilization. Subsequently, we correlated the significantly higher acylcarnitines with body mass index (BMI) and visceral fat volumes. Free carnitine levels (C0), C2, C3DC, C4, C6DC, C8, C10:1 C10:2, C14:2 and C16:1 acylcarnitines are correlated with BMI and other adiposity parameters, but not with epicardial adipose tissue volume. The BMI-related acylcarnitines correlated with cardiac alterations and revealed that C0, C2, C10:1, C14:2 and C16:1 acylcarnitine levels were associated with cardiac parameters. For instance, long-chain acylcarnitine C16:1 levels were inversely correlated with heart rate (HR, r=-0.602), left ventricle ejection fraction (LVEF, r=-0.806), left ventricle mass index (LVMI, r=-0.504), left ventricular end-diastolic diameter (LVEDD, r=-0.527) and left atrial volume index (LAVI, r=-0.530).</span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif">In conclusion, obese patients displayed an impairment of mitochondrial oxidation of fatty acids. Epicardial adipose tissue does not influence cardiac energy metabolism, revealing its neutral role in AS. Plasma acylcarnitine content change throughout a spectrum of obesity and their levels reflect AS severity. Long-chain acylcarnitine C16:1 level in coronary sinus blood correlate with worst cardiac function and structure. </span></span></p>
Our mission: To reduce the burden of cardiovascular disease
Visit our site